Grape King Bio Ltd (TPE:1707)
Taiwan
· Delayed Price · Currency is TWD 142.00
-0.50 (-0.35%)
Apr 2, 2025, 10:36 AM CST
Grape King Bio Revenue
In the year 2024, Grape King Bio had annual revenue of 11.16B TWD with 4.93% growth. Grape King Bio had revenue of 3.15B in the quarter ending December 31, 2024, a decrease of -1.42%.
Revenue
11.16B
Revenue Growth
+4.93%
P/S Ratio
1.88
Revenue / Employee
22.28M
Employees
501
Market Cap
21.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
| Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
| Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
| Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
| Dec 31, 2020 | 9.17B | -70.88M | -0.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Polaris Group | 107.00M |
| Pegavision | 6.82B |